PLATINUM-RESISTANT OVARIAN CARCINOMA
Clinical trials for PLATINUM-RESISTANT OVARIAN CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new PLATINUM-RESISTANT OVARIAN CARCINOMA trials appear
Sign up with your email to follow new studies for PLATINUM-RESISTANT OVARIAN CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Could a pneumonia drug beat back resistant ovarian cancer?
Disease control Recruiting nowThis study tests whether atovaquone, a drug normally used for infections, can help people with a type of ovarian cancer that no longer responds to standard platinum chemotherapy. About 28 adults with platinum-resistant high-grade serous ovarian cancer will take atovaquone. The go…
Matched conditions: PLATINUM-RESISTANT OVARIAN CARCINOMA
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated May 26, 2026 03:29 UTC
-
New hope for Hard-to-Treat ovarian cancer: PLX038 trial launches
Disease control Recruiting nowThis study tests a drug called PLX038 in people with ovarian, peritoneal, or fallopian tube cancer that has spread and no longer responds to platinum chemotherapy. The goal is to see if PLX038 can shrink tumors by blocking enzymes cancer cells need to grow. About 43 adults with a…
Matched conditions: PLATINUM-RESISTANT OVARIAN CARCINOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 26, 2026 03:28 UTC
-
New drug combo targets Hard-to-Treat ovarian and endometrial cancers
Disease control Recruiting nowThis early-phase study tests two experimental drugs (M1774 and ZEN-3694) together in people whose ovarian or endometrial cancer has returned. The goal is to find the safest dose and see how well the combination works. About 65 participants will take part to help determine if this…
Matched conditions: PLATINUM-RESISTANT OVARIAN CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
Ovarian cancer Patients' own immune cells supercharged to fight tumors
Disease control Recruiting nowThis early-phase study tests a new treatment for ovarian cancer that has come back or not responded to standard therapy. Doctors take a patient's own immune cells (T cells), train them in a lab to recognize a protein called MUC1 found on cancer cells, and then give them back to t…
Matched conditions: PLATINUM-RESISTANT OVARIAN CARCINOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 22, 2026 13:54 UTC